Ac-SDKP results: what to expect and when
An experimental repair peptide with old human studies, but no proven healing dose.
Also called: AcSDKP, Goralatide, Seraspenide, N-acetyl-seryl-aspartyl-lysyl-proline, Thymosin beta-4 fragment 1–4, TB4-Frag.
Healing and repair peptides · Endogenous tetrapeptide; thymosin beta-4 N-terminal fragment.
Four direct-dose records in the reviewed corpus. Biomarker studies, analogue studies, registries and reviews are excluded from that count. Cohorts may overlap.
Key studies
- Early chemotherapy trial: The abstract reports better peripheral blood-cell protection; no per-arm counts or effect sizes are given. (source)
- Chemotherapy trial: no clear protection: Across 221 chemotherapy cycles, no significant difference in blood-count nadirs or duration of low counts was reported. (source)
- Human uptake and clearance: After IV infusion, mean half-life was 4.5 minutes. SC uptake was 100%; IM uptake was 81%. (source)
- Brief infusion and ACE genotype: Exogenous Ac-SDKP broke down slightly faster in DD subjects only without captopril; baseline peptide levels did not differ. (source)
- Captopril raises natural Ac-SDKP: Plasma Ac-SDKP rose 5.5-fold, range 4–8.5-fold; hydrolysis was inhibited 90–99%. (source)
- ACE inhibition and renal clearance: Plasma rose 4-fold after one dose and 4.8-fold after 7 days. With kidney failure, chronic ACE-I levels were 22 times controls. (source)
Related to Ac-SDKP
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- TB-500: A short piece of thymosin beta-4 with no proven repair benefit in humans.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
- AHK-Cu: A copper peptide used in scalp serums, with laboratory findings and weak patent-only human data.
- Thymosin beta-4: A peptide studied for eye conditions and skin wounds; tendon-repair injections lack controlled human evidence.
- ARA-290: Experimental peptide studied for small-fiber nerve damage, with uncertain pain relief and safety.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- TGA warning on the risks of importing unapproved peptide products, Therapeutic Goods Administration · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis: MedlinePlus Medical Encyclopedia, MedlinePlus · MedlinePlus
- Cellulitis: MedlinePlus Medical Encyclopedia, MedlinePlus
- GORALATIDE, NIH NCATS
- GORALATIDE, FDA
- Recognizing medical emergencies: MedlinePlus Medical Encyclopedia, MedlinePlus
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.